Skip to main content
SpringerLink
Log in

Incidence of Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome in an HIV Cohort

An Observational, Retrospective Case Series Study

  • Short Communication
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

Background: The incidence of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) has been reported to be between 0.95 and 1 per 1000 individuals with AIDS. Accessibility to a cohort of individuals with HIV with known drug exposure (including drug, dose, and time of exposure) and collection of adverse-event information may provide an opportunity to determine an incidence rate of SJS and TEN.

Objective: The primary objective of this analysis was to determine the incidence of confirmed SJS and TEN in a cohort of Canadian HIV patients who were receiving HIV and HIV-related medications.

Study Design: This was a retrospective analysis of an HIV cohort.

Patient Population: The Ontario HIV Treatment Network (OHTN) cohort population was eligible for this analysis.

Methods: A search of the OHTN database was conducted to determine whether cases with a diagnosis of SJS or TEN were included. Search terms included ‘TEN,’ ‘SJS,’ ‘epidermal necrolysis,’ and ‘erythema multiforme.’ All SJS and TEN cases recorded in the OHTN database between January 1995 and August 2008 were obtained. Diagnostic criteria for SJS and TEN were established and two reviewers examined the medical records to confirm the SJS or TEN diagnosis. Drug exposure and utilization were documented. Incidence rates for the entire cohort were calculated.

Results: Seventeen cases over seven OHTN study sites were identified from an approximate cohort sample size of 3700. There were 15 men (88%). The mean ±SD age was 51.6 ± 11.3 years and time since HIV diagnosis was 16.1 ± 4.4 years. Only one patient reported experiencing a previous SJS or TEN episode. Of the 17 cases, clinical experts diagnosed five cases as true SJS and/or TEN, two cases were labeled as indeterminant, and the remaining cases were considered not SJS or TEN. Among the confirmed cases, drugs taken included nevirapine, trimethoprim/sulfamethoxazole (cotrimoxazole), stavudine (d4T), and clarithromycin.

Conclusions: The incidence of SJS and/or TEN was 5–7 per 3710 or approximately 1–2 per 1000 individuals in this cohort with HIV. Careful diagnosis of this adverse event is required for an accurate measure of incidence and to avoid false inflation of the incidence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

References

  1. Fritsch PO, Ruiz-Maldonado R. Stevens-Johnson syndrome-toxic epidermal necrolysis. In: Freedberg IM, Eisen AZ, Wolff K, et al., editors. Fitzpatrick’s dermatology in general medicine. 5th ed. Toronto (ON): McGraw-Hill, 1999: 644–50

    Google Scholar 

  2. Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993; 129 (1): 92–6

    Article  PubMed  CAS  Google Scholar 

  3. Roujeau JC, Chosidow O, Saiag P, et al. Toxic epidermal necrolysis (Lyell syndrome). J Am Acad Dermatol 1990; 23 (6 Pt 1): 1039–58

    Article  PubMed  CAS  Google Scholar 

  4. Schopf E, Stuhmer A, Rzany B, et al. Toxic epidermal necrolysis and Stevens- Johnson syndrome: an epidemiologic study from West Germany. Arch Dermatol 1991; 127 (6): 839–42

    Article  PubMed  CAS  Google Scholar 

  5. Naldi L, Locati F, Marchesi L, et al. Incidence of toxic epidermal necrolysis in Italy. Arch Dermatol 1990; 126 (8): 1103–4

    Article  PubMed  CAS  Google Scholar 

  6. Chan HL, Stern RS, Arndt KA, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: a populationbased study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol 1990; 126 (1): 43–7

    Article  PubMed  CAS  Google Scholar 

  7. Mittmann N, Chan B, Knowles S, et al. Intravenous immunoglobulin use in patients with toxic epidermal necrolysis and Stevens-Johnson syndrome. Am J Clin Dermatol 2006; 7 (6): 359–68

    Article  PubMed  Google Scholar 

  8. Revuz J, Penso D, Roujeau JC, et al. Toxic epidermal necrolysis: clinical findings and prognosis factors in 87 patients. Arch Dermatol 1987; 123 (9): 1160–5

    Google Scholar 

  9. Schneck J, Fagot JP, Sekula P, et al. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients including the prospective EuroSCAR study. J Am Acad Dermatol 2008; 58 (1): 33–40

    Article  PubMed  Google Scholar 

  10. Rzany B, Mockenhaupt M, Baur S, et al. Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry. J Clin Epidemiol 1996; 49 (7): 769–73

    Article  PubMed  CAS  Google Scholar 

  11. Dan M, Jedwab M, Peled M, et al. Allopurinol-induced toxic epidermal necrolysis. Int J Dermatol 1984; 23 (2): 142–4

    Article  PubMed  CAS  Google Scholar 

  12. Halevy S, Ghislain PD, Mockenhaupt M, et al. Allopurinol is the most common Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 2008; 58: 25–32

    Article  PubMed  Google Scholar 

  13. Carroll OM, Bryan PA, Robinson RJ. Stevens-Johnson syndrome associated with long-acting sulfonamides. JAMA 1966; 195 (8): 691–3

    Article  PubMed  CAS  Google Scholar 

  14. Lyell A. Sulfonamides and Stevens-Johnson syndrome [letter]. Lancet 1982; 2 (8313): 1460

    Article  PubMed  CAS  Google Scholar 

  15. Aguiar D, Pazo R, Duran I, et al. Toxic epidermal necrolysis in patients recieving anticonvulsants and cranial irradiation: a risk to consider. J Neurooncol 2004; 66 (3): 345–50

    Article  PubMed  Google Scholar 

  16. Teraki Y, Shibuya M, Izaki S. Stevens-Johnson syndrome and toxic epidermal necrolysis due to anticonvulsants share certain clinical and laboratory featureswith drug-induced hypersensitivity syndrome, despite difference in cutaneous presentations. Clin Exp Dermatol 2009; 35 (7): 723–8

    Article  Google Scholar 

  17. Ward KE, Archambault R, Mersfelder TL. Severe adverse skin reactions to nonsteroidal antiinflammatory drugs: a review of the literature. Am J Health Syst Pharm 2010; 67 (3): 206–13

    Article  PubMed  CAS  Google Scholar 

  18. Mockenhaupt M, Kelly JP, Kaufman D, et al. The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: as multinational perspective. J Rheumatol 2003; 30 (10): 2234–40

    PubMed  CAS  Google Scholar 

  19. Vinod KS, Sethuraman G, Minz A. Stevens-Johnson syndrome, toxic epidermal necrolysis and SJS-TEN overlap: a retrospective study of causative drugs and clinical outcome. Indian J Dermatol Venereol Leprol 2008; 74 (3): 238–40

    Article  Google Scholar 

  20. Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008; 128 (1): 35–44

    Article  PubMed  CAS  Google Scholar 

  21. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens- Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333 (24): 1600–7

    Article  PubMed  CAS  Google Scholar 

  22. Rzany B, Mockenhaupt M, Stocker U, et al. Incidence of Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with the acquired immunodeficiency syndrome in Germany [letter]. Arch Dermatol 1993; 129 (8): 1059

    Article  PubMed  CAS  Google Scholar 

  23. Saiag P, Caumes E, Chosidow O, et al. Drug-induced toxic epidermal necrolysis (Lyell syndrome) in patients infected with the human immunodeficiencey virus. J Am Acad Dermatol 1992; 26 (4): 567–74

    Article  PubMed  CAS  Google Scholar 

  24. Carr A, Tindall B, Penny R, et al. Patterns of multiple-drug hypersensitivities in HIV-infected patients. AIDS 1993; 7 (11): 1532–3

    PubMed  CAS  Google Scholar 

  25. Rotunda A, Hirsch RJ, Scheinfeld N, et al. Severe cutaneous reactions associated with the use of human immundeficiency virus medications. Acta Derm Venereol 2003; 83 (1): 1–9

    Article  PubMed  Google Scholar 

  26. Metry DW, Lahart CJ, Farmer KL, et al. Stevens-Johnson syndrome caused by the antiretroviral drug nevirapine. J Am Acad Dermatol 2001; 44 (2 Suppl.): 354–7

    Article  PubMed  CAS  Google Scholar 

  27. Warren KJ, Boxwell DE, Kim NY, et al. Nevirapine-associated Stevens- Johnson syndrome [letter]. Lancet 1998; 351 (9102): 567

    Article  PubMed  CAS  Google Scholar 

  28. Bastuji-Garin S, Fouchard N, Bertochhi M, et al. SCORTEN: a severity-ofillness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115: 149–53

    Article  PubMed  CAS  Google Scholar 

  29. U.S. Food and Drug Administration. MedWatch: the FDA safety information and adverse event reporting program [online]. Available from URL: (http://www.fda.gov/Safety/MedWatch/default.htm) [Accessed 2011 Oct 6]

  30. Medicines and Healthcare Products Regulatory Agency. Yellow card [online]. Available from URL: (http://yellowcard.mhra.gov.uk/) [Accessed 2011 Oct 6]

Download references

Acknowledgments

All authors were involved in the concept, design, execution, and analysis of the study, and writing of the manuscript. All authors approved the final version of the manuscript.

Investigators would like to thank Ms Peggy Kee for administrative support. The authors would like to thank the following OHTN sites that participated in this study: Sunnybrook Health Sciences Centre, Toronto General Hospital, St. Michael’s Hospital, Windsor Regional Hospital, Sudbury Regional Hospital, Maple Leaf Medical Centre, and St. Joseph’s Health Care London. The authors would also like to thank the following OHTN site investigators: Dr Anita Rachlis, Dr Irving Salit, Dr Ahmed Bayoumi, Dr Jeffery Cohen, Dr Roger Sandre, Dr Mona Loutfy, and Dr Edward Ralph. Special thanks to the OCS programmer, Kevin Challacombe.

This study was funded by the Canadian Dermatology Foundation and the Ontario HIV Treatment Network. The authors have no conflicts of interest that are directly relevant to the content of this study.

Author information

Authors and Affiliations

  1. HOPE Research Centre, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, M4N 3M5, 2075 Bayview Ave, Rm E240, Toronto, ON, Canada

    Nicole Mittmann &  Marika Koo

  2. Department of Pharmacy, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

    Sandra R. Knowles

  3. Division of Dermatology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

    Neil H. Shear

  4. Division of Infectious Diseases, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

    Anita Rachlis

  5. Ontario HIV Treatment Network, University of Toronto, Toronto, ON, Canada

    Sean B. Rourke

Authors
  1. Nicole Mittmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sandra R. Knowles
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marika Koo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Neil H. Shear
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Anita Rachlis
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sean B. Rourke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marika Koo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mittmann, N., Knowles, S.R., Koo, M. et al. Incidence of Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome in an HIV Cohort. Am J Clin Dermatol 13, 49–54 (2012). https://doi.org/10.2165/11593240-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11593240-000000000-00000

Keywords

Search

Navigation